Thyroid cancers have been particularly difficult to treat with targeted therapies, with few patients responding to MAPK pathway targeted therapies, due to a variety of resistance mechanisms, including activation of receptor tyrosine kinases, amplification of MCL1, and acquisition of the KRAS mutation in response to vemurafenib [60–63]. Here, KRAS is linked to thyroid cancer.